
|Videos|April 19, 2023
CSCC: Translating Cemiplimab Data Into Practice
Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC
5





